LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years

被引:123
|
作者
Tam, Chit [1 ]
Wong, Jack Ho [1 ]
Tsui, Stephen Kwok Wing [1 ]
Zuo, Tao [2 ]
Chan, Ting Fung [3 ]
Ng, Tzi Bun [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Shatin, Lo Kwee Seong Integrated Biomed Sci Bldg,Area 39, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Med & Therapeut, Fac Med, Shatin, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Sch Life Sci, Fac Sci, Shatin, Run Run Shaw Sci Bldg, Hong Kong, Peoples R China
关键词
lncRNA; miRNA; Epigenetic alteration; Microbiota meditation; Tumor proliferation; Metastasis; Targeted therapy design; LONG NONCODING RNA; PROMOTES CELL-PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA CELLS; PREDICTS POOR-PROGNOSIS; HELICOBACTER-PYLORI INFECTION; WNT/BETA-CATENIN PATHWAY; FACILITATES TUMOR-GROWTH; GENOME-WIDE ANALYSIS; COLON-CANCER;
D O I
10.1007/s00253-019-09837-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Long noncoding RNA (lncRNA) is a kind of RNAi molecule composed of hundreds to thousands of nucleotides. There are several major types of functional lncRNAs which participate in some important cellular pathways. LncRNA-RNA interaction controls mRNA translation and degradation or serves as a microRNA (miRNA) sponge for silencing. LncRNA-protein interaction regulates protein activity in transcriptional activation and silencing. LncRNA guide, decoy, and scaffold regulate transcription regulators of enhancer or repressor region of the coding genes for alteration of expression. LncRNA plays a role in cellular responses including the following activities: regulation of chromatin structural modification and gene expression for epigenetic and cell function control, promotion of hematopoiesis and maturation of immunity, cell programming in stem cell and somatic cell development, modulation of pathogen infection, switching glycolysis and lipid metabolism, and initiation of autoimmune diseases. LncRNA, together with miRNA, are considered the critical elements in cancer development. It has been demonstrated that tumorigenesis could be driven by homeostatic imbalance of lncRNA/miRNA/cancer regulatory factors resulting in biochemical and physiological alterations inside the cells. Cancer-driven lncRNAs with other cellular RNAs, epigenetic modulators, or protein effectors may change gene expression level and affect the viability, immortality, and motility of the cells that facilitate cancer cell cycle rearrangement, angiogenesis, proliferation, and metastasis. Molecular medicine will be the future trend for development. LncRNA/miRNA could be one of the potential candidates in this category. Continuous studies in lncRNA functional discrepancy between cancer cells and normal cells and regional and rational genetic differences of lncRNA profiles are critical for clinical research which is beneficial for clinical practice.
引用
收藏
页码:4649 / 4677
页数:29
相关论文
共 21 条
  • [1] LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years
    Chit Tam
    Jack Ho Wong
    Stephen Kwok Wing Tsui
    Tao Zuo
    Ting Fung Chan
    Tzi Bun Ng
    Applied Microbiology and Biotechnology, 2019, 103 : 4649 - 4677
  • [2] Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates
    Lee, Hee Yeon
    Woo, In Sook
    CANCERS, 2021, 13 (18)
  • [3] Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers
    Touchaei, Arefeh Zabeti
    Vahidi, Sogand
    Samadani, Ali Akbar
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [4] Cross-kingdom regulation by dietary plant miRNAs: an evidence-based review with recent updates
    Jia, MingXi
    He, JinTao
    Bai, WeiDong
    Lin, QinLu
    Deng, Jing
    Li, Wen
    Bai, Jie
    Fu, Da
    Ma, YuShui
    Ren, JiaLi
    Xiong, ShouYao
    FOOD & FUNCTION, 2021, 12 (20) : 9549 - 9562
  • [5] Biomarker discovery and validation for gastrointestinal tumors: A comprehensive review of colorectal, gastric, and liver cancers
    Hakami, Zaki H.
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 255
  • [6] Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary
    Mozsik, Gyula
    Rumi, Gyoergy
    Doemoetoer, Andras
    Figler, Maria
    Gasztonyi, Beata
    Papp, Elod
    Par, Alajos
    Par, Gabriella
    Belagyi, Jozsef
    Matus, Zoltan
    Melegh, Bela
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (48) : 7646 - 7650
  • [7] Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary
    Gyula Mózsik
    Gy(o|¨)rgy Rumi
    András D(o|¨)m(o|¨)t(o|¨)r
    Mária Figler
    Beáta Gasztonyi
    El(?)d Papp
    Alajos Pár
    Gabriella Pár
    József Belágyi
    Zoltán Matus
    Béla Melegh
    World Journal of Gastroenterology, 2005, (48) : 7646 - 7650
  • [8] The prevalence of Globo H in different tumor types: Breast, pancreatic, lung, gastric, colorectal, liver, and esophageal cancers
    Chen, I-Ju
    Yang, Ming-Chen
    Chen, Yu-Jung
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population
    Lee, Jeffrey K.
    Merchant, Sophie A.
    Schneider, Jennifer L.
    Jensen, Christopher D.
    Fireman, Bruce H.
    Quesenberry, Charles P.
    Corley, Douglas A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (05): : 706 - 715
  • [10] INTRA-HEPATO-ARTERIAL CHEMOTHERAPY WITH CDDP AND 5-FU FOR METASTASES TO THE LIVER FROM COLORECTAL AND GASTRIC CANCERS
    MAETA, M
    KOGA, S
    SHIMIZU, N
    HAMAZOE, R
    MURAKAMI, A
    ISHIGURO, M
    SAWADA, T
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07): : 1199 - 1203